EW Earnings Date: Nov 4, 2026 (Estimated) — Edwards Lifesciences Corporation
NYSE · Healthcare · Medical Devices
Updated
When is EW's next earnings date?
Edwards Lifesciences Corporation (EW) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.74 on revenue of $1.68B.
How did EW do in its last earnings report?
In its most recent report on Jul 23, 2026 (Q2 2026), Edwards Lifesciences Corporation posted EPS of $0.78 versus the $0.74 estimate, a beat of 5.4%. Revenue was $1.74B against a $1.70B estimate. The stock's 1-day post-earnings move was -1.4%.
How much does EW stock move after earnings?
EW beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.2% (up or down) in the day after earnings.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-23 | Q2 2026 | 0.74 | 0.78 | +5.41% | $1.74B | ✅ Beat | -1.42% | +3.70% | +7.12% |
| 2026-04-23 | Q1 2026 | 0.73 | 0.78 | +6.85% | $1.65B | ✅ Beat | +5.56% | +4.74% | +7.60% |
| 2026-02-10 | Q4 2025 | 0.62 | 0.58 | -6.45% | $1.57B | ❌ Miss | +2.96% | +2.50% | +9.81% |
| 2025-10-30 | Q3 2025 | 0.59 | 0.67 | +13.56% | $1.55B | ✅ Beat | -1.23% | -1.25% | +2.14% |
| 2025-04-23 | Q1 2025 | 0.60 | 0.64 | +6.67% | $1.41B | ✅ Beat | +6.63% | +7.14% | +6.15% |
| 2025-02-11 | Q4 2024 | 0.55 | 0.59 | +7.27% | $1.39B | ✅ Beat | +6.92% | +5.30% | -4.17% |
| 2024-10-24 | Q3 2024 | 0.64 | 0.67 | +4.69% | $1.35B | ✅ Beat | -1.38% | -4.75% | +0.18% |
| 2024-07-24 | Q2 2024 | 0.69 | 0.70 | +1.45% | $1.63B | ✅ Beat | -31.34% | -27.49% | -18.00% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $1.74B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | 72.3% | $1.26B | — | — | — | — | — |
| Surgical | 16.3% | $284.1M | — | — | — | — | — |
| Transcatheter Mitral and Tricuspid Therapies | 11.4% | $198.6M | — | — | — | — | — |
By region
Q2 FY26 · $1.54B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 65.2% | $1.00B | +12.8% | $643.9M | $838.9M | $889.7M | $907.5M |
| Europe | 28.6% | $439.6M | +16.2% | $298.5M | $341.8M | $378.2M | $387.9M |
| JAPAN | 6.3% | $96.4M | +1.2% | $60.2M | $81.8M | $95.3M | $90.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.